Sanjeev Trehan, MD
Interventional Cardiology · Ogden, UTNPI 1750335907
Payments from drug & device makers
Across 755 payments — averaging $125.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$27K
- Boston Scientific$26K
- Shockwave Medical, Inc$6K
- Edwards Lifesciences$6K
- Silk Road Medical, Inc.$5K
- Siemens Medical Solutions USA, Inc.$4K
- plus $20K from 49 others
What the payments were for
- Consulting fees$19,80021%
- Speaking & faculty fees$31,38133%
- Grants$550%
- Travel & lodging$14,39215%
- Food & beverage$29,10231%
- Education$1340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$26,023
- GENERAL - THERAPIES$10,667
- GENERAL VASCULAR ACCESS$7,123
- Vascular Lithotripsy$6,027
- GENERAL - STRUCTURAL HEART$4,367
- ENROUTE Transcarotid Neuroprotection System$4,253
- ENROUTE Transcarotid Stent$3,803
- ACUSON SC2000 Diagnostic Ultrasound System$2,645
- TAG Thoracic Endoprosthesis$1,858
- NAVITOR$1,849
- PASCAL$1,520
- COREVALVE EVOLUT R$1,517
- SAPIEN 3 Ultra RESILIA$1,388
- GORE TAG Thoracic Endoprosthesis$1,279
- Watchman$856
- WATCHMAN Access System$850
- Rapiblyk$745
- SOLYX$574
- ENROUTE Transcarotid Stent System$450
- ENHANCE Transcarotid Peripheral Access Kit$450
How this compares
$94,864 in reported general payments places this provider in the 80th percentile of 45 interventional cardiology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 315 | $336,917 |
| EntrestoSacubitril/Valsartan | 116 | $160,275 |
| XareltoRivaroxaban | 149 | $140,859 |
| Repatha SureclickEvolocumab | 74 | $63,438 |
| FarxigaDapagliflozin Propanediol | 45 | $38,524 |
| JardianceEmpagliflozin | 33 | $33,739 |
| Praluent PenAlirocumab | 20 | $9,985 |
| BrilintaTicagrelor | 14 | $9,951 |
| Metoprolol Succinate | 347 | $4,963 |
| VascepaIcosapent Ethyl | 12 | $4,285 |
| Atorvastatin Calcium | 412 | $4,030 |
| Ranolazine ErRanolazine | 24 | $3,938 |
| Carvedilol | 295 | $3,461 |
| ClopidogrelClopidogrel Bisulfate | 329 | $3,428 |
| Bisoprolol Fumarate | 98 | $3,182 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $453 | $336,917315 claims |
| NovartisEntresto | $582 | $160,275116 claims |
| Johnson & JohnsonXarelto | $756 | $140,859149 claims |
| AstraZenecaFarxiga, Brilinta | $194 | $48,47559 claims |
| Boehringer IngelheimJardiance | $194 | $33,73933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 45 interventional cardiology providers in Utah.
Other interventional cardiology in Ogden
- Tareq HarbOgden$27K
- Michael CrawfordOgden$8K
- Muhammad KhanOgden$7K
- Sohail KhanOgden$4K
- Charlie BrunsonOgden$3K
- Yuri KhodakovOgden$1K
- Konstantyn SzwajkunOgden$65
- Vamsee YagantiSalt Lake City$725K
- Stavros DrakosSalt Lake City$574K
- Anwar TandarSalt Lake City$488K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.